| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Lonazolac targets prostaglandin-endoperoxide synthase (COX, EC 1.14.99.1), inhibiting the production of prostaglandins. It exhibits COX-2 selectivity. By inhibiting COX enzymes, it reduces inflammation and pain. It is a nonsteroidal anti-inflammatory drug with anti-inflammatory effects.
|
|---|---|
| ln Vitro |
In vitro, Lonazolac inhibits COX-2 activity. It is a nonsteroidal anti-inflammatory drug with anti-inflammatory effects. It exhibits properties beneficial for treating pain and inflammation. It is a non-narcotic analgesic and an antineoplastic agent.
|
| ln Vivo |
In vivo, Lonazolac has anti-inflammatory effects. It is a non-steroidal antirheumatic agent used for treating pain and inflammation. It is a nonsteroidal anti-inflammatory drug with systemic activity.
|
| Enzyme Assay |
Cell-free assays for Lonazolac: COX-2 inhibition is measured using a COX-2 inhibitor screening assay kit. The enzyme is incubated with arachidonic acid and varying concentrations of the compound (0.1-100 µM). Prostaglandin production is measured by ELISA or colorimetric methods. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for Lonazolac: cells (e.g., macrophages) are cultured and treated with Lonazolac at concentrations of 0.1-100 µM for 1-24 hours, then stimulated with LPS. Prostaglandin E2 production is measured by ELISA. Cell viability is assessed by MTT assay. COX-2 expression is assessed by Western blot or qPCR.
|
| Animal Protocol |
In vivo animal studies for Lonazolac: animal models of inflammation and pain (e.g., carrageenan-induced paw edema, adjuvant-induced arthritis) are used. Animals are administered Lonazolac orally at doses of 1-10 mg/kg. Paw edema, pain response, and inflammatory markers are assessed. Efficacy and toxicity are monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Lonazolac: as a small molecule (molecular weight 312.75), it may have good oral bioavailability. It is likely metabolized in the liver and excreted via the kidneys. The compound is stored as a powder at -20°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
Toxicity of Lonazolac: as an NSAID, it may cause gastrointestinal irritation, ulceration, and bleeding. It may also have renal and cardiovascular effects at high doses. It is for research use only and not approved for clinical use.
|
| References |
|
| Additional Infomation |
Lonazolac acid is a monocarboxylic acid formed by replacing one methyl hydrogen atom in acetic acid with a 3-(4-chlorophenyl)-1-phenylpyrazole-4-yl group. It is a nonsteroidal anti-inflammatory drug (NSAID), a non-narcotic analgesic, an EC 1.14.99.1 (prostaglandin intraperoxidase) inhibitor, and an antitumor drug. It is a monocarboxylic acid belonging to the pyrazole and monochlorobenzene classes. Its function is related to acetic acid. It is the conjugate acid of Lonazolac acid (1-).
Lonazolac is a research compound with potential applications in anti-inflammatory and analgesic research. It is a nonsteroidal anti-inflammatory drug with COX-2 selectivity. No current clinical approvals have been reported. |
| Molecular Formula |
C17H13CLN2O2
|
|---|---|
| Molecular Weight |
312.75
|
| Exact Mass |
312.067
|
| CAS # |
53808-88-1
|
| Related CAS # |
Lonazolac hemicalcium;75821-71-5
|
| PubChem CID |
68706
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3g/cm3
|
| Boiling Point |
525.1ºC at 760mmHg
|
| Flash Point |
271.4ºC
|
| LogP |
3.819
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
379
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)N2C=C(C(=N2)C3=CC=C(C=C3)Cl)CC(=O)O
|
| InChi Key |
XVUQHFRQHBLHQD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H13ClN2O2/c18-14-8-6-12(7-9-14)17-13(10-16(21)22)11-20(19-17)15-4-2-1-3-5-15/h1-9,11H,10H2,(H,21,22)
|
| Chemical Name |
2-[3-(4-chlorophenyl)-1-phenylpyrazol-4-yl]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1974 mL | 15.9872 mL | 31.9744 mL | |
| 5 mM | 0.6395 mL | 3.1974 mL | 6.3949 mL | |
| 10 mM | 0.3197 mL | 1.5987 mL | 3.1974 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
